Made in USA- EMT Crews Often Unprepared for Diabetic Crises
New research suggests that when it comes to severe low blood sugar episodes in people with diabetes, first responders might not be able to administer a potentially lifesaving medication called glucagon. Glucagon is an injectable medication that prompts the liver to release stored glucose. This quickly raises blood sugar. “In most states, basic EMTs [emergency medical technicians] cannot administer glucagon,” said study senior author Dr. Robert Gabbay, chief medical officer at the Joslin Diabetes Center in Boston. Read the full story here: WebMed - Diabetes Research at Risk Due to Funding Lapse, Groups Warn
Several groups are pleading with Congress to permanently fund diabetes programs, arguing the absence of long-term funding could delay promising new research and harm prevention efforts in vulnerable populations. So far, lawmakers have provided a funding patch for the two diabetes programs that will last through March 31. But these short-term fixes come at a cost because they “do not provide the sustained ability for these programs to keep moving forward,” said Meghan Riley of the American Diabetes Association. Read the full story here: The Hill - Diabetes in Pregnancy Raises Risk of Heart Disease
Women who have had gestational diabetes have an increased risk not only for Type 2 diabetes later in life, but for heart disease and hypertension as well. Gestational diabetes is diagnosed if there is any glucose intolerance with its onset during pregnancy, and about 6 to 8 percent of pregnant women develop the condition. British researchers studied 9,118 women with gestational diabetes, comparing them with 37,281 healthy controls. The study, published in PLOS Medicine, had an average three years of follow-up. Read the full article here: The New York Times - Johnson & Johnson Is Trying to Sell Its Diabetes Care Business to Chinese Buyers for up to $4 Billion
Chinese bidders are circling a diabetes care business owned by the world’s largest healthcare company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters. New Brunswick, N.J.-based J&J said in January last year it was evaluating options for its diabetes care companies, specifically LifeScan, Animas, and Calibra Medical. One option was a sale of the business, it said. Read full story here: CNBC
Disclaimer. The content, information, and links on this page are intended for informational and educational purposes only, and does NOT constitute any medical professional advice.